News & Views

Sort by


Success for Amylyx in ALS

We take a look at the approval of Relyvrio, the third approved treatment for ALS, and the first to show both a slowing of disease progression and extended survival.


Are the Blues Ending for Bluebird?

Gene therapy developer bluebird bio may be turning a corner, with recent FDA approvals for two of its rare disease therapeutics.
Load More